General Information |
| Organization Type - Primary: |
Governmental Organization |
| Organization Type - Secondary: |
None |
| Is your organization legally registered in your country: |
Yes |
| Organization Reach: |
National |
| Organization Description: |
| SAO PAULO CITY TB CONTROL PROGRAM - MUNICIPAL HEALTH SECRETARY - 11 MILLION OF INHABITANTS - MANAGEMENT OF A HEALTH SYSTEM COVERING 510 HEALTH CENTERS, 50 PUBLIC HOSPITALS, 17 HIV/TB AMBULATORIES AND 52 LABORATORIES. |
| |
| Total number of staff in your organization: |
6 - 10 |
| Number of full-time staff who are directly involved with TB: |
1 - 5 |
| Number of part-time staff who are directly involved with TB: |
1 - 5 |
| Number of volunteers who are directly involved with TB: |
0 |
| |
| What is your organization's annual budget (USD) dedicated to TB? |
$10,001-$25,000 |
| How did you hear about the Stop TB Partnership: |
Involvement in TB control provision |
| Why do you wish join the Stop TB Partnership: |
Involvement in Stop TB Working Groups |
| |
| Are you a member of a Stop TB national partnership: |
Brazil |
| Are you in contact with your national TB programme: |
Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| By providing trainning, planning activities, organising the laboratory network, monitoring and evaluating data and actions. |
| |
Geographical Reach |
| Which country is your headquarters located in: |
Brazil |
| Which WHO region is the main focus of your work: |
American |
Which countries do you do operate in: (This includes countries you are conducting activities in) |
Brazil |
Contribution |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
DOTS Expansion and Enhancement: Active case finding for expedite diagnosis; AFB microscopy of sputum smears of all identified TB suspects; Culture is not universal, but is available according the following criteria: retreatment after relapse or drop-out, HIV/TB coinfected patients, institutional patients (penal, homeless shelters, long-term hospitals, old age homes) and health-care professionals; DOT for all patients, incentives for those adhering to regular treatment, IPT for household contacts; Information System on line; Quarterly meetings for evaluation and monitoring of activities and indicators of Tuberculosis Control Programme (TCP); Annual meeting to award prizes to units with the best results in TCP performance; Elaboration and distribution of the Yearly Epidemilogical Bulletin for TB situation up-dating; Training of health-care professionals in DOTS; Partnership with STD/AIDS Control Programme, Social Assistance Secretariat and Penitentiary System; Advocacy and Social Mobilization Meetings, organization and participation in meetings to discuss TB patients legal rights, create awareness of communitary and religious leaders to disseminate TB information.
Drug-Resistant TB: Surveillance and monitoring of multidrug resistance regarding to treatment schedule accuracy, patient follow-up and information system notification; Improvement of service network for drug-resistance attendance; Training of health-care professionals in drug-resistant patients; organization and monitoring drug distribution to MDR patients.
TB-HIV: Improving of the attending network with the partnership of AIDS Control Programme; Training of professionals in conducting tuberculin testing; Expansion of HIV testing; Implementation of IPT (isoniazide preventive therapy); Training of physicians to attend coinfected patients (TB/HIV) with drug resistant TB; Expansion of DOT procedures.
Laboratory Strengthening: Training of laboratory personnel for afb microscopy testing; Laboratory network composed of 49 units, all submitted to external quality control; From the above network, 28 units also produce micobacteria cultures; One central laboratory perform identification and susceptibility testing.
New Diagnostics: Liquid media for micobacteria culture
New TB Drugs: None
New TB Vaccines: None
Fundamental Research: None
Operational Research: None |